Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method Authors: Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna, Wagdy Eldehna Published: 2026 ABSTRACT Wild-type epidermal growth factor receptor (EGFRwt) is commonly implicated in tumor growth, yet most of the approved EGFR-targeted therapies are against mutant receptor isoforms, and patients with EGFRwt-dependent cancers have limited treatment options. We herein explored the potential to inhibit EGFRwt with five top screened hits retrieved from Food and Drug Administration (FDA)-approved kinase inhibitors library, originally developed for MET-overexpressing cancers for potential drug repurposing approach. Induced-fit docking showed that all five molecules bound the ATP-binding pocket of EGFRwt, with compound D4 emerging as the top candidate due to key interactions with ASP855 (DFG motif) and MET793 (hinge region), underscoring its favorable engagement. To further assess this interaction, we then conducted 100 ns molecular dynamics (MD) simulations, confirming the structural stability of the EGFRwt–D4 complex, with stable root-mean-square deviation (RMSD) values and maintained secondary structure elements. Free energy of binding calculations using the Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) method supported these findings, with D4 showing the most favourable interaction, dominated by Van Der Waals and electrostatic contributions from key catalytic amino acid. Our research, with further experimental validation, could be helpful to support that certain MET inhibitors, especially D4, are promising competitive inhibitors of EGFRwt, offering potential for the development of new therapeutic strategies targeting EGFRwt-driven cancers. Introduction An important therapeutic challenge is the fact that most non-small cell lung cancer (NSCLC) patients are of wild-type EGFR (wtEGFR), while the majority of EGFR-directed therapies are specifically for treating activating EGFR mutations. Studies report EGFR mutations in approximately 46% to 54% of NSCLC patients depending on disease stage, ethnicity, and smoking history, particularly prevalent within adenocarcinoma subtypes and non-smokers [1,2]. Consequently, wtEGFR exists in approximately 45% to 55% of NSCLC patients, who represent a significant clinical subgroup. For instance, among patients with early-stage NSCLC, rates of mutation are 51–54%, and 46–49% are wild-type [3,4]. Similarly, among advanced NSCLC as well, frequencies of mutations of approximately 50–53% indicate that tumors fueled by wtEGFR comprise nearly half the patients [5–8]. EGFR is a transmembrane glycoprotein receptor tyrosine kinase (RTK) that is liable for guiding critical cellular activities like growth, differentiation, migration, and survival [9,10]. Ligand binding results in conformational adjustments that will allow receptor dimerization homodimerization and heterodimerization with members of the ErbB family of receptors to trigger autophosphorylation of intracellular tyrosine residues and downstream signaling cascades. These signaling cascades, MAPK/ERK, PI3K/AKT, and JAK/STAT, play critical roles in controlling cellular homeostasis and survival [9,10]. Dysregulation of these pathways, through overexpression of the receptors, has been implicated in a variety of epithelial cancers [11,12]. The last ten years have witnessed revolutionary advances with small molecule tyrosine kinase inhibitors (TKIs) addressing specifically the common EGFR mutations like deletions in exon 19 and L858R mutation in exon 21. First and second generation of TKIs like Gefitinib, Erlotinib and Afatinib have shown improved outcomes for mutation positive patients. Third-generation inhibitors, such as osimertinib, also target resistance mechanisms like the gatekeeper T790M mutation [13,14]. Targeting wtEGFR-driven cancers remains difficult in spite of these developments. Unlike mutant EGFR, which is hyperactivated, wtEGFR is tightly regulated by normal feedback mechanisms and, in the absence of overexpression, sustained activation by autocrine/paracrine ligand signaling, or defective receptor endocytosis, contributes little to oncogenesis [12,15,16].Clinically, wtEGFR overexpression correlates with poorer prognosis, reduced radiosensitivity and chemosensitivity, and increased drug resistance to EGFR-targeting agents partly due to decreased inhibitor selectivity and on-target toxicity to normal cells [7,8,17,18]. Together with EGFR, the MET receptor tyrosine kinase plays a critical role in oncogenesis, activated by hepatocyte growth factor (HGF) to regulate cell proliferation, motility, and morphogenesis. Aberrant MET activation, through overexpression or mutation, is involved in most cancers such as lung, colorectal, and breast cancer, typically associated with aggressive tumor behavior and poor clinical outcomes [19,20]. Furthermore, MET and EGFR signaling pathways have significant crosstalk, which favors compensatory mechanisms for tumor progression and resistance to monotherapy against either receptor [21–23]. Given the structural homology in the MET and EGFR kinase domains and their common roles in cancer biology, repurposing of FDA-approved MET inhibitors to target EGFRwt is a reasonable and faster therapeutic strategy, which may bypass built-in resistance and expand the treatment arsenal. In this study, we aim to establish a rational drug repurposing framework to identify selective inhibitors targeting the wild-type epidermal growth factor receptor (wtEGFR). These inhibitors have been screened from a list of FDA-approved wild type overexpressed MET targeted TKIs. The study involves exploring the structural and energetic properties of the chosen compounds within the EGFR kinase domain through molecular docking and 100 ns molecular dynamics simulations. Additionally, binding free energies were calculated using MM/PBSA to assess the thermodynamic favorability of ligand-receptor interactions. This integrative computational method examines this set of clinically approved MET targeted TKIs as potential inhibitors for the wtEGFR kinase domain, ultimately aiding in the development of repurposed drugs for a significant untreated wt EGFR-driven cancer group of patients. Results Screening and selection of repurposed MET/EGFR inhibitors In Fig 1, we present the process of the rationale screening and clustering of the best hits. In fact, a thorough in silico and literature-based screening process was employed on first set of>100 FDA-approved kinase inhibitors that could be repurposed for cancers driven by wild-type EGFR. For that, DrugRepoBank (CUHK) was used to conduct chemical similarity searches with MET and EGFR signature compounds that have been chosen on the basis of being able to bloc the overexpressed MET receptor. Compounds with the highest similarity scores were further prioritized through structure-based virtual screening methods, including QSAR modeling and pharmacophore-based filtering, focusing on the MET catalytic domain. The selection criteria were then based on predicted stable interactions with the overexpressed MET but also the potential to influence EGFR-related signaling through pathway crosstalk (10 hits at that step; yellow circle in Fig 1). Subsequently, we conducted a targeted literature review to validate the mechanistic rationale of each candidate presented in detail in Table 1, we got best 5 hits as follow: Capmatinib was approved by the FDA in May 2020 for MET exon 14, skipping NSCLC, and has demonstrated substantial antitumor efficacy in both treatment-naïve and pretreated patients. Crizotinib, a type I multi-kinase inhibitor (ALK/MET/ROS1), has shown clinical activity in MET exon 14-mutated lung cancers. Cabozantinib and Foretinib, both type II MET inhibitors, have exhibited preclinical efficacy against MET exon 14 alterations. Then, Foretinib showing superior potency against MET kinase domain in both in vitro and in vivo models. Tivantinib, a type III allosteric MET inhibitor. 10.1371/journal.pone.0350847.t001Table 1Pharmacological Profiles and of Top 5 Selected Repurposed MET/EGFRwt cross talk Inhibitors.DrugTarget(s)Pathway(s)Key Processes AffectedEGFR Wild-Type CrosstalkCapmatinib-D1METMET/PI3K/AKT, MET/RAS/ERKTumor proliferation and survivalOvercomes EGFR-TKI resistance in MET-amplified NSCLC; may synergize with EGFR inhibitors in wild-type EGFR tumors.Crizotinib-D2ALK, ROS1, METALK/PI3K/AKT/mTOR, ALK/RAS/ERKTumor growth, migrationLimited crosstalk with wild-type EGFR; MET inhibition may influence EGFR signaling in MET-driven cancers.Cabozantinib-D3MET, VEGFR2, RET, KITMET/PI3K/AKT, VEGFR-mediated signalingTumor proliferation, angiogenesisMay overcome resistance in MET-amplified cancers; multitarget activity could suppress EGFR-driven pathways in wild-type EGFR cancers.Foretinib-D4MET, VEGFRMET/VEGFR-mediated pathwaysTumor growth, angiogenesisPotential to reduce MET-dependent EGFR signaling, particularly in cancers with wild-type EGFR.Tivantinib-D5MET (partially), MicrotubulesMET/PI3K/AKT, Cell cycle pathwaysCell survival, mitotic disruptionLimited; MET-independent effects unlikely to significantly influence wild-type EGFR signaling directly. Pharmacological Profiles and of Top 5 Selected Repurposed MET/EGFRwt cross talk Inhibitors. Screening chart for Identification of Repurposed MET/EGFR-Targeting Kinase Inhibitors. Schematic representation of the multi-step pipeline employed to identify FDA-approved tyrosine kinase inhibitors with potential inhibitory activity against wild-type EGFR. The process begins with similarity-based screening using DrugRepoBank and known MET/EGFR-targeting references. Subsequent in silico filtering applies pharmacophore and QSAR modeling with MET-binding affinity predictions. Final selection incorporates literature curation based on FDA approval, target engagement, and evidence of overcoming EGFR resistance. The resulting panel includes Capmatinib, Crizotinib, Cabozantinib, Foretinib, and Tivantinib. Therefore, as described in Table 1, these 5 drugs present an interesting serie to undertake a rigorous whole in silico study as potential EGFR kinase inhibitors repurposed from Met commercially available FDA drugs for cancer patients. This drugs set is termed as follow: Capmatinib (EGFR-D1), Crizotinib (EGFR-D2), Cabozantinib (EGFR-D3), Foretinib (EGFR-D4), and Tivantinib (EGFR-D5) and their corresponding pharmacological targets, key oncogenic pathways, and potential for crosstalk with wild-type EGFR signaling, alongside the molecular processes they influence are detailed in Table 1. Molecular docking analysis and interaction profiling We used a dual-phase molecular docking strategy to clarify the binding dynamics of repurposed MET inhibitors in the ATP-binding cleft of wild-type EGFR. Firstly, the crystal structure of EGFR (PDB ID: 4I23) was retrieved from data bank. The missing secondary structure have been cured by itasser software, as described in material and method section, in Fig 2, we show the best selected cured wt EGFR kinase model, model 1 with best confidence score (C-score) and Ramachandran plot has been retained. Structural Validation of EGFR Wild-Type Kinase Domain (PDB ID: 4I23) Using I-TASSER Server. Structural integrity of the EGFR wild-type kinase domain was verified using the I-TASSER server. (A) The top panel displays five predicted structural models generated by I-TASSER, ranked based on C-scores (confidence scores), with values ranging from –2.94 to –0.64, indicating acceptable model reliability. (B) The bottom panel shows a structural superposition between the experimentally resolved EGFR crystal structure (PDB ID: 4I23, in orange) and the highest-ranked I-TASSER predicted model (in green). The superimposed model confirms the absence of major secondary structure breakages. The confidence scoring plot (bottom right) and Ramachandran map further support the overall stereochemical quality of the crystal structure used in docking simulations. AutoDock Tools 1.5–6rc3 was then used to predict binding affinities and create initial binding poses from model 1 wtEGFr kinase and the different 5 top hits. These results were then rigorously validated using the Molecular Operating Environment (MOE) software with a fitted induced docking protocol, generating 50 poses in triplicate per ligand. Double validation guaranteed the reliability and replicability of interaction patterns. All docking steps are described in M&M section and the docking poses of the ligands were evaluated using a scoring function based on binding energy. Each pose was ranked according to its binding affinity, and the top-scoring complex was selected for further analysis. To estimate the potency of each ligand, the predicted inhibition constant (Ki) was derived from the binding free energy (ΔG) using the following equation: Where: ΔG is the binding free energy in kcal·mol −1 ΔG is the binding free energy in kcal·mol −1 R is the gas constant (1.98 cal·mol −1·K −1) R is the gas constant (1.98 cal·mol −1·K −1) T is the temperature in Kelvin (298.15 K) T is the temperature in Kelvin (298.15 K) Another key parameter used to assess ligand quality is the Ligand Efficiency (LE), which represents the binding energy per non-hydrogen atom of the ligand. It is calculated using: Where: LE is ligand efficiency in kcal·mol −1·non-H-atom −1 LE is ligand efficiency in kcal·mol −1·non-H-atom −1 ΔG is the binding free energy (kcal·mol −1) ΔG is the binding free energy (kcal·mol −1) N is the number of non-hydrogen atoms in the ligand. N is the number of non-hydrogen atoms in the ligand. Given our objective to identify best FDA-approved compounds suitable for repurposing, with a primary activity targeting the overexpressed MET receptor tyrosine kinase, this docking study aims to investigate whether such compounds could exhibit cross-reactivity or dual inhibition potential against wild-type EGFR kinase. As seen in Table 2, all the compounds tested as overexpressed MET inhibitors revealed good binding of the wild-type EGFR kinase domain with docking scores ranging from –6.65 to –8.24 kcal/mol. Foretinib (EGFR-D4) revealed the strongest binding affinity (–8.24 kcal/mol), outperforming the control ATP (–7.60 kcal/mol) and other inhibitors. Significantly, its ligand efficiency (0.37 kcal/mol/non-H atom) was also quantitatively among the highest values, suggesting Foretinib is very efficient in binding the EGFR catalytic pocket relative to its size. Capmatinib (D1) and Cabozantinib (D3) also were high-binding affinity ligands (–7.65 and –7.89 kcal/mol, respectively) with comparable ligand efficiencies. Crizotinib and Tivantinib were still desirable but relatively weaker in affinity. Interestingly, Capmatinib and Tivantinib were tied for highest predicted pKi (8.5), indicative of high competitive inhibition potential under physiologic conditions despite relatively low docking energies. Moreover, we noted that the torsional energy values were within acceptable levels for all compounds, indicating that the ligands were in energetically acceptable conformations within the EGFR binding pocket. 10.1371/journal.pone.0350847.t002Table 2Predicted Binding Affinities and Structural Metrics of Repurposed MET Inhibitors Docked to the EGFRwt Kinase Domain.Complex (protein—drug)Affinity(kcal/mol)pKiLigand Efficiency (kcal/mol/non-H atom)Torsional Energy (kcal/mol) EGFRwt-D1 (Capmatinib) −7.65282158.50.402.0 EGFRwt-D2 (Crizotinib) −6.75767238.00.352.5 EGFRwt-D3 (Cabozantinib) −7.89431388.10.382.5 EGFRwt-D4 (Foretinib) −8.24482067.50.372.0 EGFRwt-D5 (Tivantinib) −6.65174348.50.402.0 EGFRwt-D6 (Reference) −7.60770616.90.301.5 Predicted Binding Affinities and Structural Metrics of Repurposed MET Inhibitors Docked to the EGFRwt Kinase Domain. As illustrated in Fig 3, the 2D interaction maps clearly demonstrate that all five ligands Capmatinib (EGFRwt-D1), Crizotinib (EGFRwt-D2), Cabozantinib (EGFRwt-D3), Foretinib (EGFRwt-D4), and Tivantinib (EGFRwt-D5) are well accommodated within the ATP-binding cleft, but differ markedly in the density and diversity of their intermolecular interactions. Foretinib (EGFRwt-D4) exhibits the most extensive interaction network, forming multiple conventional hydrogen bonds with the hinge-associated residue GLN791 and GLY857, along with additional stabilization through CYS797. Notably, it shows strong engagement with the DFG motif through interactions with ASP855 and Gly857, including π–π stacking and halogen (fluorine) contacts, indicating deep positioning within the activation loop. Additional stabilization arises from π-cation interaction with LYS745 and π-alkyl contacts involving LEU788, ALA743, and VAL726 (Fig 3, EGFRwt-D4). Representative 2D visualizations of the binding conformations of the five repurposed tyrosine kinase inhibitors: Capmatinib (EGFRwt-D1), Crizotinib (EGFRwt-D2), Cabozantinib (EGFRwt-D3), Foretinib (EGFRwt-D4), and Tivantinib (EGFRwt-D5) within the ATP binding pocket of wild-type EGFR. The native ATP molecule is included for reference to illustrate differential interaction patterns. Key residues: Gatekeeper THR790, DFG:855-857 and hinge region anchor residues: MET793 and GLN791 has been involved in different interactions such hydrogen bonding and hydrophobic interactions are annotated. Visualisation interaction analyses was performed using Discovery Studio. Crizotinib (EGFRwt-D2) also demonstrates a relatively rich interaction profile, forming conventional hydrogen bonds with the hinge residue GLN791 and MET793, and interacting with the DFG residue ASP855. It further exhibits π-cation interaction with LYS745, while hydrophobic stabilization is maintained through π-alkyl interactions with LEU718, VAL726, and ALA743. However, its interaction with the DFG motif is less extensive than that of Foretinib, particularly lacking strong engagement with ASP855 and/or GLY857. While, cabozantinib (EGFRwt-D3) presents a more compact yet efficient interaction pattern. Capmatinib (EGFRwt-D1) shows moderate interaction density, primarily through interaction with MET793 and limited involvement of GLN791, whereas Tivantinib (EGFRwt-D5) displays comparatively fewer interactions, with weak hinge engagement and partial contact with the DFG region on ASP855. The ATP reference ligand maintains a balanced interaction network, including hydrogen bonding with hinge residues GLN791 and MET793, and interactions with DFG residues ASP855 and GLY857, serving as a structural and functional benchmark. Visualizations of the specific intermolecular contacts formed by each ligand within the catalytic cleft are presented in Fig 4, which provides a detailed description of key hydrogen bonds, salt bridges, hydrophobic contacts, and water-mediated interactions for each complex. In fact, in Fig 4, these interaction patterns are further contextualized within the three-dimensional structure of EGFR. The right panel presents the full protein architecture, highlighting key functional regions including the ATP-binding pocket, hinge region, gatekeeper residue (THR790), and the activation loop containing the DFG motif. The left panel provides a detailed 3D view of the binding pocket, where key residues are emphasized, allowing visualization of ligand orientation and depth of insertion. Consistent with the 2D interaction analysis, Foretinib (EGFRwt-D4) demonstrates the most extensive engagement with critical residues, spanning both the hinge region (GLN791, MET793) and the DFG motif (ASP855, GLY857), confirming its optimal positioning within the active site. Crizotinib (EGFRwt-D2) follows, showing substantial with the gatekeeper THR790 but less comprehensive interaction with these regions, while Cabozantinib (EGFRwt-D3), Capmatinib (EGFRwt-D1) and Tivantinib (EGFRwt-D5) exhibit more limited engagement. Overall, based on the qualitative interaction richness, we note that the structural insights from Fig 4 reinforce the trends observed in Fig 3, supporting the ranking of interaction strength and binding engagement as D4 > D2 > D1 > D5 > D3. 3D Binding Modes of Repurposed Drugs within the ATP-Binding Site of Wild-Type EGFR Kinase Domain. Docking poses of five repurposed kinase inhibitors: Capmatinib (EGFR-D1, red), Crizotinib (EGFR-D2, yellow), Cabozantinib (EGFR-D3, orange), Foretinib (EGFR-D4, green), and Tivantinib (EGFR-D5, cyan) within the ATP-binding pocket of the EGFR kinase domain are shown. Interacting residues forming hydrogen bonds within 3.5 Å are labeled. The left panel displays the full EGFRwt kinase, highlighting key structural regions: hinge region (green), gatekeeper THR790 (red), and DFG motif (blue). The right panel shows the superimposed binding orientations of all compounds within the pocket, with interactions involving key residues highlighted in yellow. MD simulations The top-ranked binding pose for each protein–drug complex, as identified from the docking study, was subsequently subjected to comprehensive molecular dynamics simulations. These calculations are to examine how each compound performs under dynamic, physiologically realistic conditions so much more than static docking can tell us alone. By tracking the behavior of the complexes over 100 ns, we could observe how the ligands interacted with EGFRwt in motion, and how the protein responded accordingly and more interestingly the whole resolution of the initially retrieved protein from cristal data bank could be slightly enhanced after the MD simulations. Structural stability and flexibility of EGFRwt/ligand complexes Simulations conducted for 100 ns at 310K of these five drugs within the EGFr kinase binding site and with respect to the key indicators such as root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), ligand RMSD, and radius of gyration (Rg) were used to measure global stability and local flexibility. Results showed us first of all that the RMSD profiles, as depicted in Fig 5A, indicated that all the ligand-bound states of EGFRwt were stable during the course of the simulation, with fluctuation between 0.2 and 0.5 nm practically the same as in the unbound protein. This indicates that the binding of the ligand was not destabilizing the kinase domain, a requirement for a good inhibitor. At the residue level, RMSF analysis (Fig 5B) was found to be not significant for changes in flexibility in all the complexes, with the average fluctuations less than 0.4 nm. This consistency suggests that none of the ligands induced unwanted local perturbation to the protein backbone, signifying that the compounds are structurally compatible with the EGFRwt binding site. Structural stability and flexibility analysis of EGFR in complex with compounds D1, D2, D3, D4, and D5, compared to EGFR alone. A: Root-mean-square deviation (RMSD) of the EGFR backbone in complex with compounds D1, D2, D3, D4, and D5, compared to EGFR alone. B: Root-mean-square fluctuation (RMSF) of the EGFR backbone in complex with compounds D1, D2, D3, D4, and D5, compared to EGFR alone. C: Radius of gyration (Rg) of the EGFR backbone in complex with compounds D1, D2, D3, D4, and D5, compared to EGFR alone. D: Root-mean-square deviation (RMSD) of the ligand compounds D1, D2, D3, D4, and D5 during the MD simulations. Then when we look at ligand-specific RMSD (Fig 5D), which informs us about how well every compound remained in the ATP-binding pocket, we notice that D2 and D5 showed the lowest fluctuations, remaining less than 0.2 nm throughout, which reveals strong and stable binding. D1 and D4 experienced slightly greater, but still moderate, 0.2 to 0.4 nm fluctuations showing minor conformational alterations within the pocket more commonly associated with flexible adaptive binding. Importantly, D3 exhibited low drift until approximately 40 ns before stabilizing at a higher level, implying delayed but steady repositioning. Despite these minor adjustments, D4 exhibited an excellent balance between flexibility and retention, maintaining orientation within the binding pocket with reassuring stability throughout the window of simulation. Lastly, radius of gyration (Rg) information (Fig 5C) confirmed that the global compactness of EGFRwt remained intact throughout the simulation. Rg measures for every complex were between 1.95 and 2.10 nm, and D1, D2, and D4 in particular exhibited patterns that closely mirrored that of the free protein. Thus, out of all the studied complexes, Foretinib-D4 once more exhibited stable and low-fluctuation behavior and further proved the structural compatibility and its capacity to form a tightly packed, stable complex. Hydrogen bounds analysis One of the interesting outputs of MD simulations is to quantitively explore the binding affinity of these drugs in complexe with the protein through the H-bond interaction profiles. These H-bond Interactions help to gain further insights into the nature and ligand binding stability in the EGFRwt active site. For that, we monitored the hydrogen bond formation along the 100 ns molecular dynamics trajectory. Results depicted in Fig 6 showed us that All five complexes-maintained hydrogen bonds for the duration of the simulation, although their number and stability varied among compounds. Time-Resolved Analysis of Hydrogen Bond Interactions between EGFRwt and Ligands D1–D5 during Molecular Dynamics Simulations. Hydrogen bond formation profiles of EGFRwt in complex with repurposed ligands D1 (Capmatinib), D2 (Crizotinib), D3 (Cabozantinib), D4 (Foretinib), and D5 (Tivantinib) over the course of the 100 ns molecular dynamics simulation. The number of hydrogen bonds was calculated per frame to evaluate the persistence and strength of ligand–protein interactions. Among all, EGFRwt–D4 exhibited the most consistent and sustained hydrogen bonding network, suggesting enhanced interaction stability, in agreement with docking and structural dynamics analyses. Of note, D1 and D2 showed a similar pattern, oscillating between one and two hydrogen bonds, sometimes peaking at four. D3, however, showed a definitive increase in hydrogen bonding post the 50 ns milestone, stabilizing at two to four bonds suggesting the ligand may have been positively reshaped in the binding site. D4 (Foretinib) surprisingly showed a steep increase in hydrogen bond contacts following the simulation midpoint, culminating to five stable bonds. D5 showed enhanced bonding post 40 ns, up to as many as three stable contacts. These patterns indicate that D3, D4, and D5 could structurally modify during the course of the simulation to produce more effective, longer-lasting hydrogen bonding. Time-delayed but stabilized hydrogen bond creation points toward time-dependent accommodation, in which the ligands develop tighter, more favorable interactions with the receptor, potentially contributing to their increased binding affinity and complex stability. PCA projection of trajectory and free energy landscapes analysis Finally, MD simulation informed us on the dynamical behavior of the protein-ligand complexes, via the Principal Component Analysis (PCA) and constructed Free Energy Landscapes (FEL) of the most important collective motions that we investigated also in this study. The approach provides information on how ligand binding defines the collective conformational landscape of EGFRwt and allows us to identify the most energetically favorable states visited along the course of the simulation. By projecting the trajectories onto the first two principal components, we noted the dominant motions and used these to generate FELs that highlight the basins of conformation visited by each complex (Fig 7). Free energy landscapes of EGFRwt complexes with D1–D5 obtained from Molecular Dynamics simulations. The plots (a–e) illustrate the Gibbs free energy surfaces projected along the first two principal components (PC1 and PC2), corresponding to the dominant motions of each complex. Distinct energy minima, visualized in red, represent stable conformational states sampled during the simulation, while blue regions indicate higher energy conformations. The number and depth of the minima reflect the conformational flexibility and binding stability of each ligand. Red color indicates regions of low free energy, stable conformations. For all complexes, ligand binding smoothly modified EGFRwt’s surface of energy, causing distortions in the distribution and depth of energy minima. This is an indication of a structural reorganization of the receptor in order to accommodate diverse ligands. At 20 ns of the simulation work, the FEL profiles demonstrated that all complexes but especially and interestingly the D3, D4 and D5 hits are well stabilized within their lowest-energy states, with no indications of structural destabilization or unfolding (Fig 8). Free Energy Landscape of EGFRwt-D1-D5 Complexes During the Last 20 ns Of The Molecular Dynamic Simulation. Free energy landscapes of EGFRwt-D1 to D5 complexes during the final 20 ns of molecular dynamics simulation. The energy surfaces were constructed using principal component analysis (PCA) based on atomic fluctuations. Local minima, represented by red regions, indicate the most thermodynamically favorable conformations sampled during the equilibrium phase of each complex. Variations in the depth and distribution of energy basins reflect differences in the conformational stability and dynamic behavior of the ligand-bound EGFR-wt systems. Binding free energy analysis (MM/PBSA) Ultimately, to quantitatively elucidate the energetic basis of EGFRwt ligand interaction patternsfollowing their qualitative assessment through 2D and 3D visualizations (Figs 3 and 4, respectively), we performed MM/PBSA calculations. This approach enabled the decomposition of the total binding free energy into its principal contributions, including van der Waals, electrostatic, polar solvation, and non-polar solvation components (Table 3). 10.1371/journal.pone.0350847.t003Table 3Decomposition of Binding Free Energy for EGFRwt-Ligand Complexes.D1-EGFRwtD2-EGFRwtD3-EGFRwtD4-EGFRwtD5-EGFRwt ΔVDWAALS −18.12 ± 0.53−31.72 ± 0.26−28.85 ± 2.69−37.75 ± 0.61−34.27 ± 0.03 ΔEEL −10.28 ± 1.6828.70 ± 3.16−27.57 ± 2.44−26.41 ± 3.03−25.25 ± 0.69 ΔEGB 20.84 ± 4.66−9.61 ± 0.8150.80 ± 2.3639.88 ± 0.6740.88 ± 0.10 ΔESURF −2.19 ± 0.53−4.17 ± 0.07−4.16 ± 0.04−4.87 ± 0.11−4.39 ± 0.11 ΔGGAS −28.39 ± 1.80−3.02 ± 3.17−56.42 ± 3.66−64.15 ± 3.10−59.52 ± 0.73 ΔGSOLV 18.65 ± 4.69−13.78 ± 0.8146.64 ± 2.3635.01 ± 0.6836.49 ± 0.15 ΔTOTAL −9.74 ± 5.02−16.79 ± 3.27−9.78 ± 4.36−29.15 ± 3.17−23.03 ± 0.75 Decomposition of Binding Free Energy for EGFRwt-Ligand Complexes. Among the five ligands, D4 (Foretinib) possessed the most favorable overall binding free energy (–29.15 ± 3.17 kcal/mol), and this was closely followed by D5 (Tivatinib, –23.03 ± 0.75 kcal/mol). The two possessed the highest affinities, which were mainly driven by strong gas-phase interactions (ΔGGAS), including van der Waals and electrostatics. Both D4 and D5 possessed other strongest ΔGGAS values (–64.15 and –59.52 kcal/mol, respectively), suggesting strong non-covalent attraction in the binding site. Van der Waals interactions played the largest role in complex stability, with D4 taking the lead at –37.75 kcal/mol, closely followed by D5 at –34.27 kcal/mol. Although electrostatic contributions varied, D2 had a highly destabilizing trend (+28.70 kcal/mol), likely due to repulsive Coulombic interactions. Solvation effects, especially polar solvation (ΔEGB), were inclined to oppose binding, with D3 being the hardest hit (+50.80 kcal/mol). On the other hand, D2 had a minor stabilizing solvation contribution (–9.61 kcal/mol). Together, these active conformations validate that D4 and D5 represent the best-suited repurposed inhibitors, in which binding is largely governed by van der Waals interactions and acceptable penalties of solvation. Discussion The problem of targeting wild-type epidermal growth factor receptor (EGFRwt) in cancer therapy adequately is a recurring one. As much as mutant EGFR, i.e., that expressed in non-small cell lung cancer has driven waves of effective drug discovery, EGFRwt continues to be out of reach of effective pharmacologic manipulation. Its resistance to presently utilized EGFR inhibitors like Gefitinib, Erlotinib, and even third-generation agents like Osimertinib illustrates a therapeutic window in oncology [12,19]. But this is no minor gap: EGFRwt plays a central role in numerous aggressive cancers glioblastoma, colorectal cancer, and triple-negative breast cancer and its inhibition could radically change outcomes [20,21]. Facing these limitations, we turned to an approach that unites scientific pragmatism and rational drug discovery: drug repurposing. Rather than seeking new scaffolds de novo, we looked inward to the existing pharmacopoeia for molecules of unexploited potential. In particular, we have checked whether the FDA-approved MET inhibitors may cross the molecular chasm and bind EGFRwt, exploiting their structural relatedness and common interaction in oncogenic signaling pathways [22–24]. This is not only an efficient but also timely approach repositioning well-studied drugs can do so much to quicken clinical translation, bypassing many of the initial developmental steps. We accessed the DrugRepoBank database to filter MET-targeting compounds for structural compatibility, pharmacokinetic favorability, and established anticancer activity. Five lead compounds: Capmatinib, Crizotinib, Cabozantinib, Foretinib, and Tivantinib, termed D1 to D5 respectively, emerged as strong contenders. Multitarget kinase profiles and well-tolerated safety profiles further enhanced their candidacy [25–27]. Molecular docking simulations provided the first insight into the binding potential of the tested compounds. All five ligands stably occupied the ATP-binding cleft of EGFRwt, recapitulating key interactions typically observed with the native ligand. Among them, Foretinib stood out not only due to its favorable binding free energy but also because of the richness of its interaction network. The overall molecular conformation of Foretinib suggested not merely a fit, but an optimal geometry tailored for effective inhibition. Other compounds showed varying degrees of engagement with critical residues reflecting moderate stabilization within the ATP-binding site. Collectively, the docking results emphasize the importance of simultaneous engagement with the hinge region (GLN791, MET793), gatekeeper (THR790), and DFG motif (ASP855, PHE856, GLY857) for effective inhibition. Among the tested compounds, Foretinib demonstrated the most extensive and favorable interactions across these key residues, supporting its potential as the lead candidate for repurposing against EGFRwt [28,29]. Then the study was strengthened by molecular dynamics (MD) simulations, which tracked how these early docking poses withstood the test of time. Foretinib excelled again with low RMSD and little fluctuation throughout the 100-ns window. This stability resolved a strong and functionally significant interaction with the kinase domain of EGFRwt. Root mean square fluctuation (RMSF) information also guaranteed that Foretinib binding reduced local residue flexibility, particularly in the activation loop-indicating a locked, inhibition-prone conformation [30,31]. Conversely, the hydrogen bonds that lasted for a long time with the hinge region suggested a stable, high-affinity interaction against displacement. Principal Component Analysis (PCA) introduced another aspect of this tale. Foretinib-bound EGFRwt complexes, when projected onto collective motion space, demonstrated significantly smaller dynamic fluctuations compared to others a marker of conformational constraint. Free Energy Landscapes (FELs) built from these trajectories exhibited an intriguing pattern: whereas other ligands traversed wide and shallow energy basins, Foretinib plunged into a deep, sharp energetic trough, reflecting a highly favorable thermodynamic situation (Fig 7II). These FEL profiles, particularly those built using the final 20 ns of the simulation, observed the equilibrium dynamics of the complexes and confirmed the long-term conformational stability of the Foretinib–EGFRwt interaction [32,33]. To set these obtained results in terms of numbers, we turned to MM/PBSA free energy calculations. Foretinib again came out on top, with the lowest binding free energy for all energetic terms. Van der Waals and electrostatics were behind its strong binding, and modest solvation penalties ensured that these were not reversed. The overall picture was one of a ligand with both thermodynamic preference and kinetic stability a complementary and valuable combination in kinase inhibition [34–36]. The therapeutic potential of dual inhibition by Foretinib is especially amenable. Tumors will tend to become resistant by diverting their signals along different receptor tyrosine kinases. In such cases, dual-targeted treatment forms a necessity in certain patient cases, a mechanism of blocking escape pathways and imposing long-lasting responses [37–39]. Foretinib’s pharmacokinetic and safety profiles, already tested in previous-phase trials, form an imminently translatable platform into EGFRwt-driven malignancies. Of course, these computational results, as compelling as they are, must ultimately be validated through experimental investigations. In this context, the concept of drug repurposing remains particularly significant, as it enables the rapid and cost-effective identification of new therapeutic applications for existing compounds, thereby facilitating a more efficient translation from in silico predictions to experimental and clinical validation such through biochemical kinase assays, viability assays for cancer cells, and in vivo models of tumors will be required to confirm Foretinib’s efficacy of inhibition and selectivity. Structural studies through crystallography or cryo-EM may even refine its manner of binding, and toxicity studies will determine its therapeutic index. If the following studies confirm our findings, Foretinib could indeed have a new purpose not as a standalone MET inhibitor, but as a dual agent that might open a blocked horizon for some anticancer treatment. Finally, this work is more than computation. It is a call to reassess the overlooked, to repurpose the known, and to imagine alternative applications for old machines. EGFRwt, long resistant to inhibition, can still fall to molecules within our grasp. Conclusion This study contributes to identify more the importance of repurposing FDA-approved MET inhibitors as anti-wild-type EGFR drugs, a receptor that is generally overlooked in present targeted therapies but is relevant in several cancers. With a robust computational method involving DrugRepoBank-based screening, molecular docking, and long molecular dynamics simulations, we identified Foretinib as a probable dual inhibitor. Among all the candidates tested, Foretinib had the most favorable binding to the EGFR ATP-pocket with a conformation close to crucial interactions of the native ligand. Its EGFRwt complex was time-stable with minimal structural fluctuations and stable hydrogen bonds and implied favorable dynamics for effective kinase inhibition. Supporting biophysical characterizations by principal component analysis and free energy landscape mapping confirmed the EGFRwt–Foretinib complex conformation stability. Additionally, MM/PBSA binding energy calculations confirmed its improved interaction profile over other screened compounds. Together, these results suggest that Foretinib not only possesses high binding affinity to EGFRwt but also benefits from a dynamic and energetic profile that supports therapeutic effectiveness. With its existing clinical history and dual MET/EGFR targeting capabilities, Foretinib could candidate for repositioning therapy for EGFRwt-driven tumors. Such a strategy would likely broaden the scope of precision oncology by offering a ready and cost-effective treatment in cancers where such targeted therapy that currently is less explored. Materials and methods Drug selection and screening strategy To identify appropriate drug candidates for repurposing in EGFR wild-type cancers, a three-step strategy was employed, integrating computational screening with literature-based filtering. Initially, the DrugRepoBank platform (https://awi.cuhk.edu.cn/DrugRepoBank) facilitated chemical similarity searches based on established MET and EGFR pathway inhibitors. Compounds exhibiting high similarity scores underwent further evaluation through structure-based virtual screening methods, including QSAR modeling and pharmacophore alignment, to predict their affinity for the overexpressed MET kinase domain. Subsequently, a targeted literature review was conducted to assess the mechanistic relevance of the shortlisted compounds, emphasizing their documented ability to modulate MET signaling and interact with EGFR-related pathways. Only drugs with FDA approval for other cancer types and established pharmacological profiles were retained for further analysis. This integrative approach enabled the selection of five hits out of more than 100 candidates as promising candidates for repurposing in EGFR wild-type cancer models. Molecular docking Molecular docking was conducted to identify potential therapeutic candidates targeting the wild-type epidermal growth factor receptor (EGFRwt). In this study targeting wild-type EGFR, the 4WRG structure (1.9 Å resolution) was initially selected; however, it exhibited significant gaps in secondary structural elements. These deficiencies were addressed using the I-TASSER (https://zhanggroup.org/I-TASSER) server to reconstruct missing regions and correct chain discontinuities. Despite this refinement, comparative analysis indicated that the 4I23 (2.8 Å resolution) structure more closely resembles the wild-type human EGFR. Moreover, as our objective is to accurately target key residues involved in competitive inhibition, 4I23 was ultimately selected as the more suitable structure for this study. This latter was prepared using AutoDock Tools 1.5–6rc3 and preparation steps involved the removal of crystallographic water molecules, the addition of polar hydrogens, and the assignment of Gasteiger partial charges to ensure accurate representation of the receptor’s electronic environment. The ligand library comprising five (n = 5 + ATP reference) FDA-approved drugs was curated to explore drug repurposing potential. Ligands were energy-minimized and converted to the appropriate file format for docking. Docking simulations were first performed using AutoDock Tools 1.5–6rc3. The workspace was defined by a grid box centered on the ATP-binding site of EGFR, with coordinates set to center_x = 1.640, center_y = 54.060, and center_z = –22.010. The grid box dimensions were 40 Å × 50 Å × 50 Å along the X, Y, and Z axes, respectively, providing comprehensive coverage of the active site and surrounding key residues. Docking parameters included an energy range of 4 kcal/mol and an exhaustiveness of 8 to optimize the balance between accuracy and computational efficiency. Binding affinities were ranked based on predicted binding free energies (kcal/mol), and the top-ranked compounds were selected for further analysis. To enhance the docking outcomes and simulate a scenario that more closely resembles physiological interactions, an additional round of induced-fit docking was performed using the Molecular Operating Environment (MOE 2024.06) software. Each ligand was docked into the ATP-binding site of the wild-type EGFR while ATP was present to consider competitive binding. For every compound, 50 poses were generated three times, allowing for the conformational flexibility of both the ligand and the protein side chains. This induced-fit docking approach facilitated a more precise evaluation of binding competitiveness and structural accommodation within the active site. Optimal binding poses were visualized using BIOVIA Discovery Studio Visualizer (discovery-studio-visualizer 2025) to characterize key molecular interactions, including hydrogen bonding, hydrophobic contacts, and π-π stacking, between the ligands and EGFR active site residues. Molecular dynamics simulations To assess the stability and dynamic behavior of the protein-ligand complexes, molecular dynamics (MD) simulations were performed using GROMACS 2020 with the CHARMM36 force field for protein parameterization and the Swissparam for ligand topology generation. The complexes were solvated in a TIP3P water model within a cubic box, and Na + /Cl− ions were added to neutralize the system. Energy minimization was conducted using the steepest descent algorithm to remove steric clashes and optimize the system. Equilibration was performed in two phases: constant volume and temperature (NVT) ensemble for 100 ps, followed by continuous pressure and temperature (NPT) ensemble for another 100 ps, using the V-rescale thermostat and Parrinello-Rahman barostat, respectively, to maintain physiological conditions. MD simulations were run for 100 ns at 310 K to evaluate ligand stability within the EGFR binding site. Post-simulation analyses included root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), hydrogen bonding interactions, principal component analysis (PCA), and free energy landscape (FEL) estimations. Binding free energy calculations Post-MD simulations, binding free energy calculations were carried out to quantitatively evaluate the binding affinities of the chosen inhibitors and to supplement the docking outcomes. These calculations utilized the molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) and molecular mechanics generalized Born surface area (MM/GBSA) methods, executed through the gmx_mmpbsa package. To ensure statistical reliability, 100 evenly distributed snapshots were taken from the last 20 ns of molecular dynamics (MD) simulation trajectories. This sampling period was selected to reflect the equilibrated state of the protein-ligand complexes. The decomposition of binding free energy included essential energetic components: van der Waals interactions, electrostatic interactions, polar solvation energy, and non-polar solvation energy. These detailed energetic profiles allowed for the analysis of the thermodynamic contributions influencing ligand binding, offering crucial insights into the molecular factors that determine complex stability. Statistical analysis Statistical analysis was conducted on all quantitative data derived from docking scores, molecular dynamics simulations, and binding free energy analyses using a one-way analysis of variance (ANOVA). To determine statistically significant differences among group means, Duncan’s multiple range test was employed for multiple comparisons. A p-value of less than 0.05 was considered significant. All statistical analyses were performed using SPSS software, version 17.0 for Windows. 3 Mar 2026 -->PONE-D-26-01840-->-->Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross-Talk Pathway Strategy and an In-Silico Drug Repurposing Method-->-->PLOS One Dear Dr. Abdelmalek, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 17 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Wagdy M. Eldehna, Ph.d Academic Editor PLOS One Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. 3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Partly ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: N/A Reviewer #2: N/A ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: No Reviewer #2: No ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Dear Author, Thank you for your submission. While the docking study is promising, several methodological concerns must be addressed to strengthen the manuscript. Protein Structure Selection The chosen EGFR kinase domain structure (PDB ID: 4I23) has a resolution of 2.80 Å, which is suboptimal for precise docking studies due to potential inaccuracies in atomic coordinates, particularly in the ATP-binding pocket. Higher-resolution structures (<2.0 Å) or those with improved electron density for key residues should be prioritized. Target Pocket Visualization Clearer images of the target binding pocket are needed, explicitly labeling essential amino acids (e.g., hinge region residues, gatekeeper, DFG motif). Current figures lack sufficient detail for readers to assess interaction validity. Binding Mode Analysis Notably, the docked hit compounds show no interactions with critical ATP-site residues MET793 or GLN791, which are essential for EGFR inhibitor stability (as seen in co-crystallized dacomitinib). This absence undermines claims of suitable binding poses and compound efficacy. Recommendations Replace 4I23 with a higher-resolution EGFR structure . Add annotated 2D interaction diagrams and 3D pocket views highlighting all key contacts. Revise docking validation to confirm hinge hydrogen bonds and hydrophobic packing with MET793/GLN791. Reviewer #2: There is a jump from computational prediction to the implications of therapeutic effectiveness. There is no benchmarking with established EGFRwt inhibitors; therefore, the binding affinity and dynamics cannot be fully evaluated. No comparison with known EGFR inhibitors ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Abdulrahman M. Saleh Reviewer #2: Yes: Mahmoud Rashed ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 25 Mar 2026 Response to Decision Letter and Reviewer Comments (Manuscript number: PONE-D-26-01840) Manuscript title: Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross-Talk Pathway Strategy and an In-Silico Drug Repurposing Method Dear Respected Professor Wagdy M. Eldehna, Academic Editor Journal of Plos one March, 25, 2026 We greatly appreciate your kind request to revise our manuscript in the light of those constructive and insightful peer review comments. We are thankful for showing interest in our work. We have taken into consideration all suggestions and comments and have critically edited and revised the manuscript accordingly to comply with all suggestions. Also a thorough revision of the whole manuscript has been conducted. We would therefore be pleased to resubmit a revised version of our improved manuscript which addresses all concerns and requests. Those changes are highlighted within the manuscript in yellow. Please find below our response, for every single point raised by the reviewers. All page numbers refer to the final revised manuscript file with track changes in yellow. We would be glad if you could consider our revised manuscript for possible publication in the Journal of Plos one Once again, thank you indeed for your kind consideration. On behalf of all co-authors, Corresponding author: Dr. Dorra Abdelmalek Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, 3041 Sfax, Tunisia Email: dorra.abdelmalek@cbs.rnrt.tn Reviewer #1: Dear Author, Thank you for your submission. While the docking study is promising, several methodological concerns must be addressed to strengthen the manuscript. R1.Protein Structure Selection The chosen EGFR kinase domain structure (PDB ID: 4I23) has a resolution of 2.80 Å, which is suboptimal for precise docking studies due to potential inaccuracies in atomic coordinates, particularly in the ATP-binding pocket. Higher-resolution structures (<2.0 Å) or those with improved electron density for key residues should be prioritized. A1. We sincerely appreciate your insightful and constructive comment. Prior to selecting the protein structure that serves as the foundation of this study, a thorough and rigorous evaluation of available database entries was conducted to ensure suitability. We fully understand that high resolution structures are strongly recommended for molecular docking and molecular dynamics simulations. In our investigation, which specifically targets the wild-type epidermal growth factor receptor (EGFR) in its crystallographic form, we initially considered the 4WRG structure, characterized by a resolution of 1.9 Å. However, this structure exhibited substantial deficiencies in secondary structural elements, including α-helices, β-sheets, and loop regions. To address these limitations, the 4WRG structure was refined using the I-TASSER server (https://zhanggroup.org/I-TASSER) to reconstruct missing secondary structures and resolve chain discontinuities. Nevertheless, upon comparative analysis with the 4I23 structure (afetr being cured with I-tasser), we determined that the latter exhibits a higher degree of structural similarity to the wild-type human EGFR, thereby making it more appropriate for our study. There are also other strcuture but with resolution >2A like cited in the table below : PDB ID Resolution Notes 4WRG 1.90 Å Wild-type kinase domain 9BY4 2.31 Å WT EGFR + non-covalent osimertinib 9BY6 2.55 Å WT EGFR soaked with inhibitor 2GS2 2.80 Å Active EGFR kinase domain Taking this concern into account, as kindly highlighted, we have addressed and clarified this point in the revised manuscript Molecular Docking M&M section, page 17-18, lines 550-557. Furthermore, as the present work primarily relies on molecular dynamics simulations and related calculations that require high structural reliability, the selected 4I23 structure demonstrated notable stability and yielded meaningful results throughout the study. As known, molecular dynamics simulations performed using GROMACS contributed to a slight improvement in structural refinement. The docking analysis was subsequently complemented by a rigorous dynamic evaluation of both the backbone protein and its ligand-bound complexes. Key parameters including root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), ligand RMSD, and radius of gyration (Rg) along with Principal Component Analysis (PCA) and Free Energy Landscape (FEL) construction, provided detailed insights into the protein’s dynamical behavior. These additions have been incorporated into the main manuscript page 10, lines 289–293. R2.Target Pocket Visualization Clearer images of the target binding pocket are needed, explicitly labeling essential amino acids (e.g., hinge region residues, gatekeeper, DFG motif). Current figures lack sufficient detail for readers to assess interaction validity. A2. We appreciate the reviewer’s valuable comment regarding the need for clearer visualization of the target binding pocket and explicit labeling of essential amino acids. In response, Figures 3 hasbeen thoroughly revised to improve clarity, structural interpretation, and interaction transparency as we re-undertook more induced-fit docking protocol (100 runs) to refine ligand conformations within the binding pocket and ensure robustness of the observed interactions. The revised Figure 3 (2D interaction maps) now provides detailed residue-level interactions, clearly showing hydrogen bonds, π-cation, π–π stacking, and hydrophobic contacts involving the key residues mentioned above. Notably, strong and recurrent interactions with ASP855 (DFG motif), including electrostatic and π-related contacts, were observed for the top-performing compounds. Specifically, we have refocused the analysis on key functional residues within the EGFR active site, including the hinge region (GLN791, MET793), the gatekeeper residue (THR790), and the DFG motif (ASP855, PHE856, GLY857). These residues are now explicitly highlighted and labeled in the updated figures to allow readers to better assess ligand–protein interaction validity. A new Figure 4 has also been introduced to provide a comprehensive structural context: the left panel displays the full EGFR protein with major functional regions annotated, while the right panel offers a detailed 3D visualization of the binding pocket with key residues highlighted. This dual representation allows for better assessment of ligand positioning relative to critical structural elements. Please check the revised version of the manuscript on Results section pages 8-9- lines 236-281 and discussion at page 14-15 lines 451-462. R3. Binding Mode Analysis Notably, the docked hit compounds show no interactions with critical ATP-site residues MET793 or GLN791, which are essential for EGFR inhibitor stability (as seen in co-crystallized dacomitinib). This absence undermines claims of suitable binding poses and compound efficacy. A3. We thank the reviewer for this important and insightful observation regarding the absence of interactions with key hinge residues MET793 and GLN791, which are indeed critical for stabilizing ATP-competitive EGFR inhibitors. We acknowledge as previously described that the initial interaction plots did not adequately capture these contacts, primarily due to the specific docking poses selected for visualization. To address this, we have performed additional and more rigorous induced-fit docking (100 runs) as mentionned in the previous remark, allowing better sampling of ligand conformations within the ATP-binding pocket. As a result, the revised analyses now clearly demonstrate interactions with the hinge region, particularly involving GLN791 and MET793, as well as the gatekeeper residue THR790 and the DFG motif (ASP855, PHE856, GLY857). These interactions are now explicitly highlighted in the updated figures. Specifically, revised Figure 3 provides an improved 2D representation of the binding pocket, where ligand positioning relative to these key residues is clearly visible. In addition, a new Figure 4 has been included to explicitly present the 3D interaction profiles of all compounds with the critical hinge residues (GLN791, MET793) and other essential structural elements. Reviewer #2: There is a jump from computational prediction to the implications of therapeutic effectiveness. R1. There is no benchmarking with established EGFRwt inhibitors; therefore, the binding affinity and dynamics cannot be fully evaluated. No comparison with known EGFR inhibitors. A1. We sincerely appreciate your valuable comment regarding the importance of benchmarking against established EGFRwt inhibitors. As correctly noted, the present study is grounded in a drug repurposing strategy, transitioning from c-MET targeted compounds to EGFR, specifically the wild-type receptor. The investigated molecules were selected from a library of Food and Drug Administration (FDA)-approved kinase inhibitors. Given the high degree of structural conservation within the kinase family, our objective was to explore the potential of these approved compounds to interact effectively with EGFRwt through rigorous in silico simulations, thereby identifying promising candidates in a time- and cost-efficient manner. We fully acknowledge the importance of benchmarking ; however, the primary scope of this work is predictive screening. Importantly, we emphasize the critical role of subsequent bench experimental validation to confirm these findings. In this regard, we have added a dedicated paragraph in the revised manuscript (page 16, lines 495–501) highlighting the necessity of experimental benchmarking against established EGFR inhibitors to substantiate and extend the computational results. Submitted filename: respond to reviewers.docx 8 May 2026 -->PONE-D-26-01840R1-->-->Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross-Talk Pathway Strategy and an In-Silico Drug Repurposing Method-->-->PLOS One Dear Dr. Abdelmalek, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 22 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Wagdy M. Eldehna, Ph.d Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: N/A Reviewer #2: N/A Reviewer #3: I Don't Know ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Dear Authors, I am pleased to inform you that your manuscript entitled “Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross Talk Pathway Strategy and an In-Silico Drug Repurposing Method” has been accepted for publication. Reviewer #2: (No Response) Reviewer #3: The revised manuscript by Abdelmalek et al. represents a meaningful response to the concerns raised in the first review cycle. The authors have addressed the two most critical methodological weaknesses: the structural justification for PDB ID 4I23 is now clearly articulated in the Materials and Methods section, and the binding mode analysis has been significantly strengthened through re-execution of induced-fit docking at 100 runs, with the revised figures now explicitly demonstrating interactions with the pharmacologically essential hinge residues GLN791 and MET793, the gatekeeper THR790, and the DFG motif. The addition of Figure 4 providing dual 2D/3D visualization of the binding pocket represents a genuine improvement in interpretive clarity. The computational pipeline, combining DrugRepoBank screening, dual-software docking validation, 100 ns GROMACS molecular dynamics, PCA/FEL analysis, and MM/PBSA free energy decomposition, is methodologically appropriate for a repurposing study of this scope, and Foretinib's emergence as the lead candidate is consistently and convergently supported across all metrics. The drug repurposing rationale exploiting MET/EGFR pathway crosstalk is scientifically well-grounded and clinically relevant given the underserved EGFRwt patient population. However, prior to final acceptance, three minor but necessary corrections must be addressed: The AutoDock Tools version placeholder ("version X.X") at line 558 must be completed. The textual claim that D4 exhibits the highest ligand efficiency should be reconciled with Table 2, which shows D1 and D5 at 0.40 versus D4 at 0.37 The ranking of interaction strength stated in the text at lines 280–281 (D4 > D2 > D1 > D5 > D3) is based on qualitative structural engagement rather than raw docking affinity scores, which follow a different order in Table 2 (D4 > D3 > D1 > D2 > D5). While this distinction is scientifically defensible, it is never explicitly acknowledged in the text and is likely to confuse readers. I believe that a brief clarifying sentence noting that the two rankings reflect different evaluation criteria, quantitative binding affinity versus qualitative interaction richness, would resolve this ambiguity. Additionally, despite the authors' acknowledgement of language editing support, several typographical errors persist throughout the manuscript(e.g., "describved," "strenghted," "trmed," "Simualtions," "rigourous," "biddable" and "leftt") and should be corrected before publishing the paper. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: Yes: Abdulrahman M. Saleh Reviewer #2: Yes: Mahmoud Rashed Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 12 May 2026 Response to Decision Letter and Reviewer Comments (Manuscript number: PONE-D-26-01840R1) Manuscript title: Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross-Talk Pathway Strategy and an In-Silico Drug Repurposing Method Dear Respected Professor Wagdy M. Eldehna, Academic Editor Journal of Plos one Mai, 12, 2026 We greatly appreciate your kind appreciation of the revision made to make the paper as its best scientific level. In this minor revision, we have taken also into consideration all Highly Respectful suggestions and comments raised by the reviewer. We would therefore be pleased to resubmit a revised version of our improved manuscript which addresses all concerns and requests. Those changes are highlighted within the manuscript in yellow. Please find below our response, for every single point raised by the reviewer. All page numbers refer to the final revised manuscript file with track changes in yellow. We would be glad if you could consider our revised manuscript for possible publication in the Journal of Plos one Once again, thank you indeed for your kind consideration. On behalf of all co-authors, Corresponding author: Dr. Dorra Abdelmalek Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, University of Sfax, 3041 Sfax, Tunisia Email: dorra.abdelmalek@cbs.rnrt.tn Reviewer #3: The revised manuscript by Abdelmalek et al. represents a meaningful response to the concerns raised in the first review cycle. The authors have addressed the two most critical methodological weaknesses: the structural justification for PDB ID 4I23 is now clearly articulated in the Materials and Methods section, and the binding mode analysis has been significantly strengthened through re-execution of induced-fit docking at 100 runs, with the revised figures now explicitly demonstrating interactions with the pharmacologically essential hinge residues GLN791 and MET793, the gatekeeper THR790, and the DFG motif. The addition of Figure 4 providing dual 2D/3D visualization of the binding pocket represents a genuine improvement in interpretive clarity. The computational pipeline, combining DrugRepoBank screening, dual-software docking validation, 100 ns GROMACS molecular dynamics, PCA/FEL analysis, and MM/PBSA free energy decomposition, is methodologically appropriate for a repurposing study of this scope, and Foretinib's emergence as the lead candidate is consistently and convergently supported across all metrics. The drug repurposing rationale exploiting MET/EGFR pathway crosstalk is scientifically well-grounded and clinically relevant given the underserved EGFRwt patient population. However, prior to final acceptance, three minor but necessary corrections must be addressed: R1. The AutoDock Tools version placeholder ("version X.X") at line 558 must be completed. A1. Yes, indeed it is Autodock tools -1.5.6rc3. we corrected this in the revised manuscript at lines 186, 554 and 559. R2. The textual claim that D4 exhibits the highest ligand efficiency should be reconciled with Table 2, which shows D1 and D5 at 0.40 versus D4 at 0.37 The ranking of interaction strength stated in the text at lines 280–281 (D4 > D2 > D1 > D5 > D3) is based on qualitative structural engagement rather than raw docking affinity scores, which follow a different order in Table 2 (D4 > D3 > D1 > D2 > D5). While this distinction is scientifically defensible, it is never explicitly acknowledged in the text and is likely to confuse readers. I believe that a brief clarifying sentence noting that the two rankings reflect different evaluation criteria, quantitative binding affinity versus qualitative interaction richness, would resolve this ambiguity. A2. Thank you for this interesting remark and for the suggestion to resolve the ambiguity. For that we corrected that D ligand efficiency score is among the best quantitative score, lines 221 and 222. And for the qualitative scoring order we changed the text as follow: “Overall, based on the qualitative interaction richness, we note that the structural insights from Figure 4 reinforce the trends observed in Figure 3, supporting the ranking of interaction strength and binding engagement as D4 > D2 > D1 > D5 > D3. » lines 279-281 in the revised manuscript. R3. Additionally, despite the authors' acknowledgement of language editing support, several typographical errors persist throughout the manuscript (e.g., "describved," "strenghted," "trmed," "Simualtions," "rigourous," "biddable" and "leftt") and should be corrected before publishing the paper. A3. Thank you for taking care of these typing mistakes. As per recommended all these typo errors has been carefully corrected and highlighted in yellow. Submitted filename: Response to Reviewers.docx 20 May 2026 Identifying Potential Inhibitors for Wild-Type EGFR Tyrosine Kinase through a Cross-Talk Pathway Strategy and an In-Silico Drug Repurposing Method PONE-D-26-01840R2 Dear Dr. Abdelmalek, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Wagdy M. Eldehna, Ph.d Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #3: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #3: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #3: I Don't Know ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #3: No ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #3: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #3: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #3: No ********** PONE-D-26-01840R2 PLOS One Dear Dr. Abdelmalek, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Wagdy M. Eldehna Academic Editor PLOS One